Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
retatrutide nearby vs. Tirzepatide: The Next-Gen GLP-1 Showdown Quantity:6 Month Supply research-grade Retatrutide, a TRIPLE agonist
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished
15 The dose of this product is also based on the insulin component in units, and the recommended starting dose is dependent on the patient’s background therapy at the time of drug initiation
research-grade
Quantity:6 Month Supply
In other words, GLP-1 medications are not being studied as hormone therapy
